Asia Pacific Immunohistochemistry Market Size Report, 2024-2033
The Asia Pacific immunohistochemistry market size was estimated at USD 509.80 million in 2023 and is expected to surpass around USD 1,195.86 million by 2033 and poised to grow at a compound annual growth rate (CAGR) of 8.9% during the forecast period 2024 to 2033.
The Asia Pacific Immunohistochemistry Market is witnessing a robust expansion driven by the increasing significance of immunohistochemical techniques in the field of diagnostics and research. Immunohistochemistry (IHC) plays a pivotal role in visualizing the distribution and expression of specific antigens within tissue samples, aiding clinicians, pathologists, and researchers in gaining valuable insights into various diseases, particularly cancer.
Increase in the prevalence of chronic conditions, such as cancer, certain infectious diseases, autoimmune diseases, cardiovascular diseases, nephrological diseases, and diabetes mellitus has led to a wider use of Immunohistochemistry (IHC) techniques in diagnostics. The incidence of cancer is rising steadily, which is expected to boost demand for effective diagnostic methods, including immunohistochemistry. This technique is significant in the determination of oncogenesis & diagnosis of cancer, such as malignant or benign, and their different stages. It facilitates the use of polyclonal and monoclonal antibodies to detect specific antigens in tissues by determining the presence of tumor antigens.
Rise in healthcare spending across the globe is driving demand for the implementation of immunohistochemistry techniques in healthcare sector. According to estimates published by WHO in 2020, global spending on healthcare witnessed a significant increase, accounting for 11% of global GDP or USD 9 trillion. Moreover, developing countries in Asia such as India, Indonesia, Vietnam, and Philippines are increasing their healthcare expenditure to improve overall health services. The healthcare industry is evolving from a fee-for-service model to a value-based model, wherein treatment outcomes are reimbursed. The pressure of reducing healthcare costs is rising globally as the cost of healthcare is increasing faster than the growth of economies.
Various advanced techniques, such as multiplex IHC, computational pathology, and next-generation IHC, have revolutionized the field of conventional IHC. Multiplex IHC can multiply the amount of data derived from a single or limited tissue sample, thus benefitting cellular interactions. For instance, MultiOmyx by NeoGenomics is a multiplexing technique that aids in the analysis of proteins and biomarkers in a single tumor section. In addition, in September 2023, Cell Signaling Technology (CST) introduced SingalStar Multiplex IHC technology for high-throughput IHC assays.
Moreover, key players in the market are introducing novel IHC reagents and antibodies for pharma and biotech industries. For instance, in March 2023, Aptamer Group plc launched Optimer-Fc as a new reagent for automated IHC workflows. In addition, Biocare Medical, LLC in collaboration with Bethyl Laboratories introduced a TIGIT IVD rabbit monoclonal antibody for IHC applications. Such initiatives are driving the immunohistochemistry market growth.
| Report Attribute | Details |
| Market Size in 2024 | USD 555.17 million |
| Market Size in 2033 | USD 1,195.86 million |
| Growth Rate From 2024 to 2033 | CAGR of 8.9% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, application, end-use, country |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; Danaher Corporation; PerkinElmer, Inc.; Bio-Rad Laboratories, Inc.; Cell Signaling Technology, Inc.; Bio SB; Agilent Technologies, Inc.; Abcam plc.; HiMedia Laboratories; IMGENEX INDIA Pvt. Ltd.; Sino Biological, Inc.; NICHIREI BIOSCIENCES INC. (NICHIREI CORPORATION); MEDICAL ＆ BIOLOGICAL LABORATORIES CO., LTD.; Immuno-Biological Laboratories Co, Ltd.; Kyowa Kirin Co., Ltd.; Amos Scientific PTY. LTD.; PathnSitu Biotechnologies Pvt Ltd |
Antibodies led the Asia Pacific market and accounted for 42% of the market in 2023 and is expected to grow at the fastest CAGR over the forecast period. This high percentage can be attributed to their significant use in disease diagnosis and drug testing. Antibodies are further segmented into primary and secondary antibodies. These form a vital base in various applications such as pathology, neuropathology, and hematopathology. As immunohistochemistry involves antibody-antigen reactions to detect diseases, it is preferred over other conventional forms of staining procedures, thereby aiding in Asia Pacific market growth.
Antibodies are typically used to detect diseases by identification of tumor-specific antigens, tumor suppressor genes, enzymes, tumor cell proliferation markers, and oncogenes. A large number of primary and secondary antibodies are available in market, which aid in drug development, disease diagnosis, and life sciences research.
Reagents held the second-largest market share in the IHC market during the study period owing to their frequent usage in various procedures. These are essentially used to deliver consistent staining and accurate results in the least amount of time. Most reagents supplied by manufacturers are validated and optimized through consideration of their usage in a particular IHC procedure. Reagents include blocking sera & reagents, fixation reagents, chromogenic substrates, stabilizers, organic solvents, diluents, and proteolytic enzymes. A wide range of reagents are available in the market, customized for each step involved in IHC.
Diagnostics segment accounted for the largest market revenue share in 2023. Immunohistochemistry is widely used for diagnosis of chronic conditions, such as cancer, cardiovascular diseases, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases. It plays a significant role in cancer diagnosis as it detects specific tumor antigens in certain cancers. During breast cancer diagnosis, IHC staining is used on fresh or frozen tissue, which is removed during biopsy. It helps in identifying HER2 or hormone receptor proteins on surface of cancer cells. Thus, prominent applications of immunohistochemistry in diagnostics are driving segment growth.
Research segment is expected to register the fastest CAGR during the forecast period. Researchers in academia, pharmaceutical companies, and healthcare institutions depend on IHC to advance knowledge in various fields such as oncology, neurology, immunology, and pathology. Governments and academic institutions are investing heavily in medical research, which is supporting the segment growth.
Furthermore, the introduction of new products can strengthen the competitive landscape in Asia Pacific market. This can lead to innovation and improved quality. For instance, in March 2021, QIAGEN introduced QIAcube Connect MDx. This platform is used in diagnostic labs for automated sample processing. It is also compatible with a wide range of QIAGEN kits.
Hospitals segment accounted for the largest share of the Asia Pacific market in 2023. With constant changes in healthcare industry, need for hospitals with advanced facilities has increased. Moreover, the rise in the number of hospitalizations has led to high growth of segment in the Asia Pacific market. With growing prevalence of chronic diseases, such as cancer, infectious diseases, and autoimmune diseases, there is a surge in demand for hospitals & diagnostic centers for the detection of antigens for cancer diagnosis.
Immunohistochemical staining is largely used to identify abnormal cells found in cancerous growth. This has further increased the need for diagnostic centers with advanced instruments to perform such tests. Rise in number of cancer cases is a significant factor driving growth of this segment.
Research institutes sector is projected to witness the fastest CAGR over the forecast period owing widespread use of immunohistochemistry techniques in drug testing. Research institutes engage in collaborations and consortia to pool resources, expertise, and data. These collaborations drive adoption of immunohistochemistry techniques for large-scale studies and clinical trials, contributing to Asia Pacific market growth. For instance, in June 2023, Lunaphore Technologies SA and Cell Signaling Technology, Inc. announced a collaboration to provide researchers with a powerful toolset for conducting comprehensive spatial biology studies, enabling them to gain deeper insights into complex interactions between cells and their environment in various disease states.
Japan dominated the market and accounted for 29.42% share in 2023 owing to high government spending to reduce disease burden. Rapidly aging population, increasing expectations for improved quality of life, and government initiatives are propelling immunohistochemistry market. Japan, in contrast to other Asia Pacific countries, offers country-wide cancer screening programs to combat the growing prevalence of cancer. This program offers cancer screening to over 94% of the population in country, thereby driving regional growth. Moreover, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the market. For instance, in February 2021, SCREEN Holdings Co., Ltd. announced a joint initiative with Kyoto Prefectural University of Medicine (KPUM) with an aim to accelerate precision medicine by combining multiplex immunohistochemistry with AI image analysis technologies.
China is anticipated to witness significant growth in the Asia Pacific market. Some key factors responsible for lucrative market growth in China are the rapidly aging population, a growing number of laboratories, and improving medical infrastructure. According to NCBI, one in ten individuals living in China meets the criteria for obesity. The high prevalence of obesity has led to a rise in the prevalence of chronic conditions, such as stroke, diabetes, and atrial fibrillation. The increasing prevalence of chronic diseases and the presence of a high target population, along with high unmet clinical needs, are expected to support immunohistochemistry market growth.
Some of the key players operating in the Asia Pacific immunohistochemistry market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, and Danaher Corporation.
Bio SB, Agilent Technologies, Inc., HiMedia Laboratories, IMGENEX INDIA Pvt. Ltd. are some of the emerging market participants in the Asia Pacific immunohistochemistry market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Asia Pacific Immunohistochemistry market.
By Product
By Application
By End-use
By Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. End Use
1.2.4. Country scope
1.2.5. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. nova one advisor internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in Asia Pacific
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Application outlook
2.2.3. End Use outlook
2.2.4. Country outlook
2.3. Competitive Insights
Chapter 3. Asia Pacific Immunohistochemistry Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increase in prevalence of chronic diseases
3.2.1.2. Growing geriatric population
3.2.1.3. Rise in healthcare spending
3.2.1.4. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Limitations of standardization with IHC techniques
3.2.2.2. High cost of automated IHC instruments
3.2.3. Market challenge analysis
3.2.3.1. Lack of standardization in IHC technique
3.2.3.2. Limited scope for multiple evaluation
3.3. Asia Pacific Immunohistochemistry Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Asia Pacific Immunohistochemistry Market: Product Estimates & Trend Analysis
4.1. Product Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Asia Pacific Immunohistochemistry Market by Product Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Antibodies
4.4.1.1. Antibodies Market estimates and forecasts 2020 to 2033
4.4.1.2. Primary Antibodies
4.4.1.2.1. Primary Antibodies Market estimates and forecasts 2020 to 2033
4.4.1.3. Secondary Antibodies
4.4.1.3.1. Secondary Antibodies Market estimates and forecasts 2020 to 2033
4.4.2. Equipment
4.4.2.1. Market estimates and forecasts 2020 to 2033
4.4.2.2. Slide Staining System
4.4.2.2.1. Slide Staining System Market estimates and forecasts 2020 to 2033
4.4.2.3. Tissue Microarrays
4.4.2.3.1. Tissue Microarrays Market estimates and forecasts 2020 to 2033
4.4.2.4. Tissue Processing Systems
4.4.2.4.1. Tissue Processing Systems Market estimates and forecasts 2020 to 2033
4.4.2.5. Slide Scanners
4.4.2.5.1. Slide Scanners Market estimates and forecasts 2020 to 2033
4.4.2.6. Others
4.4.2.6.1. Others Market estimates and forecasts 2020 to 2033
4.4.3. Reagents
4.4.3.1. Reagents Market estimates and forecasts 2020 to 2033
4.4.3.2. Histological Stains
4.4.3.2.1. Histological Stains Market estimates and forecasts 2020 to 2033
4.4.3.3. Blocking Sera and Reagents
4.4.3.3.1. Blocking Sera and Reagents Market estimates and forecasts 2020 to 2033
4.4.3.4. Chromogenic Substrates
4.4.3.4.1. Chromogenic Substrates Market estimates and forecasts 2020 to 2033
4.4.3.5. Fixation Reagents
4.4.3.5.1. Fixation Reagents Market estimates and forecasts 2020 to 2033
4.4.3.6. Organic Solvents
4.4.3.6.1. Organic Solvents Market estimates and forecasts 2020 to 2033
4.4.3.7. Proteolytic Enzymes
4.4.3.7.1. Proteolytic Enzymes Market estimates and forecasts 2020 to 2033
4.4.3.8. Diluents
4.4.3.8.1. Diluents Market estimates and forecasts 2020 to 2033
4.4.3.9. Other Reagents
4.4.3.9.1. Other reagents Market estimates and forecasts 2020 to 2033
4.4.4. Kits
4.4.4.1. Kits Market estimates and forecasts 2020 to 2033
Chapter 5. Asia Pacific Immunohistochemistry Market: Application Estimates & Trend Analysis
5.1. Application Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Asia Pacific Immunohistochemistry Market by Application Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Diagnostics
5.4.1.1. Diagnostics Market estimates and forecasts 2020 to 2033
5.4.1.2. Cancer
5.4.1.2.1. Cancer Market estimates and forecasts 2020 to 2033
5.4.1.3. Infectious Diseases
5.4.1.3.1. Infectious Diseases Market estimates and forecasts 2020 to 2033
5.4.1.4. Cardiovascular Diseases
5.4.1.4.1. Cardiovascular Diseases Market estimates and forecasts 2020 to 2033
5.4.1.5. Autoimmune Diseases
5.4.1.5.1. Autoimmune Diseases Market estimates and forecasts 2020 to 2033
5.4.1.6. Diabetes Mellitus
5.4.1.6.1. Diabetes Mellitus Market estimates and forecasts 2020 to 2033
5.4.1.7. Nephrological Diseases
5.4.1.7.1. Nephrological Diseases Market estimates and forecasts 2020 to 2033
5.4.1.8. Others
5.4.1.8.1. Others Market estimates and forecasts 2020 to 2033
5.4.2. Research
5.4.2.1. Research Market estimates and forecasts 2020 to 2033
Chapter 6. Asia Pacific Immunohistochemistry Market: End Use Estimates & Trend Analysis
6.1. End Use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Asia Pacific Immunohistochemistry Market by End Use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Hospitals & Diagnostic Laboratories
6.4.1.1. Hospitals & Diagnostic Laboratories Market estimates and forecasts 2020 to 2033
6.4.2. Research Institutes
6.4.2.1. Research Institutes Market estimates and forecasts 2020 to 2033
6.4.3. Others
6.4.3.1. Others Market estimates and forecasts 2020 to 2033
Chapter 7. Asia Pacific Immunohistochemistry Market: Country Estimates & Trend Analysis
7.1. Country Market Share Analysis, 2023 & 2030
7.2. Country Market Dashboard
7.3. Country Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. Japan
7.5.1. Key country dynamics
7.5.2. Regulatory framework/ reimbursement structure
7.5.3. Competitive scenario
7.5.4. Japan market estimates and forecasts 2020 to 2033
7.6. China
7.6.1. Key country dynamics
7.6.2. Regulatory framework/ reimbursement structure
7.6.3. Competitive scenario
7.6.4. China market estimates and forecasts 2020 to 2033
7.7. India
7.7.1. Key country dynamics
7.7.2. Regulatory framework/ reimbursement structure
7.7.3. Competitive scenario
7.7.4. India market estimates and forecasts 2020 to 2033
7.8. South Korea
7.8.1. Key country dynamics
7.8.2. Regulatory framework/ reimbursement structure
7.8.3. Competitive scenario
7.8.4. South Korea market estimates and forecasts 2020 to 2033
7.9. Australia
7.9.1. Key country dynamics
7.9.2. Regulatory framework/ reimbursement structure
7.9.3. Competitive scenario
7.9.4. Australia market estimates and forecasts 2020 to 2033
7.10. Singapore
7.10.1. Key country dynamics
7.10.2. Regulatory framework/ reimbursement structure
7.10.3. Competitive scenario
7.10.4. Singapore market estimates and forecasts 2020 to 2033
7.11. Thailand
7.11.1. Key country dynamics
7.11.2. Regulatory framework/ reimbursement structure
7.11.3. Competitive scenario
7.11.4. Thailand market estimates and forecasts 2020 to 2033
7.12. Malaysia
7.12.1. Key country dynamics
7.12.2. Regulatory framework/ reimbursement structure
7.12.3. Competitive scenario
7.12.4. Malaysia market estimates and forecasts 2020 to 2033
7.13. Indonesia
7.13.1. Key country dynamics
7.13.2. Regulatory framework/ reimbursement structure
7.13.3. Competitive scenario
7.13.4. Indonesia market estimates and forecasts 2020 to 2033
7.14. Philippines
7.14.1. Key country dynamics
7.14.2. Regulatory framework/ reimbursement structure
7.14.3. Competitive scenario
7.14.4. Philippines market estimates and forecasts 2020 to 2033
7.15. Vietnam
7.15.1. Key country dynamics
7.15.2. Regulatory framework/ reimbursement structure
7.15.3. Competitive scenario
7.15.4. Vietnam market estimates and forecasts 2020 to 2033
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2023
8.3.4. Thermo Fisher Scientific Inc.
8.3.4.1. Company overview
8.3.4.2. Financial performance
8.3.4.3. Product benchmarking
8.3.4.4. Strategic initiatives
8.3.5. F. Hoffmann-La Roche Ltd.
8.3.5.1. Company overview
8.3.5.2. Financial performance
8.3.5.3. Product benchmarking
8.3.5.4. Strategic initiatives
8.3.6. Merck KGaA
8.3.6.1. Company overview
8.3.6.2. Financial performance
8.3.6.3. Product benchmarking
8.3.6.4. Strategic initiatives
8.3.7. Danaher Corporation
8.3.7.1. Company overview
8.3.7.2. Financial performance
8.3.7.3. Product benchmarking
8.3.7.4. Strategic initiatives
8.3.8. PerkinElmer, Inc.
8.3.8.1. Company overview
8.3.8.2. Financial performance
8.3.8.3. Product benchmarking
8.3.8.4. Strategic initiatives
8.3.9. Bio-Rad Laboratories, Inc.
8.3.9.1. Company overview
8.3.9.2. Financial performance
8.3.9.3. Product benchmarking
8.3.9.4. Strategic initiatives
8.3.10. Cell Signaling Technology, Inc.
8.3.10.1. Company overview
8.3.10.2. Financial performance
8.3.10.3. Product benchmarking
8.3.10.4. Strategic initiatives
8.3.11. Bio SB
8.3.11.1. Company overview
8.3.11.2. Financial performance
8.3.11.3. Product benchmarking
8.3.11.4. Strategic initiatives
8.3.12. Agilent Technologies, Inc.
8.3.12.1. Company overview
8.3.12.2. Financial performance
8.3.12.3. Product benchmarking
8.3.12.4. Strategic initiatives
8.3.13. Abcam plc.
8.3.13.1. Company overview
8.3.13.2. Financial performance
8.3.13.3. Product benchmarking
8.3.13.4. Strategic initiatives
8.3.14. HiMedia Laboratories
8.3.14.1. Company overview
8.3.14.2. Financial performance
8.3.14.3. Product benchmarking
8.3.14.4. Strategic initiatives
8.3.15. IMGENEX INDIA Pvt. Ltd.
8.3.15.1. Company overview
8.3.15.2. Financial performance
8.3.15.3. Product benchmarking
8.3.15.4. Strategic initiatives
8.3.16. Sino Biological, Inc.
8.3.16.1. Company overview
8.3.16.2. Financial performance
8.3.16.3. Product benchmarking
8.3.16.4. Strategic initiatives
8.3.17. NICHIREI BIOSCIENCES INC. (NICHIREI CORPORATION)
8.3.17.1. Company overview
8.3.17.2. Financial performance
8.3.17.3. Product benchmarking
8.3.17.4. Strategic initiatives
8.3.18. MEDICAL ＆ BIOLOGICAL LABORATORIES CO., LTD.
8.3.18.1. Company overview
8.3.18.2. Financial performance
8.3.18.3. Product benchmarking
8.3.18.4. Strategic initiatives
8.3.19. Immuno-Biological Laboratories Co,Ltd.
8.3.19.1. Company overview
8.3.19.2. Financial performance
8.3.19.3. Product benchmarking
8.3.19.4. Strategic initiatives
8.3.20. Kyowa Kirin Co., Ltd.
8.3.20.1. Company overview
8.3.20.2. Financial performance
8.3.20.3. Product benchmarking
8.3.20.4. Strategic initiatives
8.3.21. Amos Scientific PTY. LTD.
8.3.21.1. Company overview
8.3.21.2. Financial performance
8.3.21.3. Product benchmarking
8.3.21.4. Strategic initiatives
8.3.22. PathnSitu Biotechnologies Pvt Ltd
8.3.22.1. Company overview
8.3.22.2. Financial performance
8.3.22.3. Product benchmarking
8.3.22.4. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers